Cover Image

The Complementary Effects of Dabigatran Etexilate and Exercise Training on the Development and Stability of the Atherosclerotic Lesions in Diabetic ApoE Knockout Mice

<b>Aim:</b> To determine the complementary effects of dabigatran etexilate (DE), exercise training (ET), and combination (DE + ET) on the development and stability of the atherosclerotic lesions in diabetic apoE knockout (apoE<sup>−/−</sup>) mice. <b>Methods:</b>...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nikolaos PE Kadoglou (Author), Marianna Stasinopoulou (Author), Evangelia Gkougkoudi (Author), Eirini Christodoulou (Author), Nikolaos Kostomitsopoulos (Author), Georgia Valsami (Author)
Format:	Book
Published:	MDPI AG, 2023-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Discovery of Dabigatran Etexilate
by: Joanne evan Ryn, et al.
Published: (2013)

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS
by: N. M. Vorobieva, et al.
Published: (2015)

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice
by: Preusch MR, et al.
Published: (2015)

Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
by: Himabindu Reddy, et al.
Published: (2015)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015)

Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines
by: Alesha J. Smith, et al.
Published: (2020)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016)

Potential Pharmaceutical Applications of Quercetin in Cardiovascular Diseases
by: Paraskevi Papakyriakopoulou, et al.
Published: (2022)

A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block
by: Nikolaos P. E. Kadoglou, et al.
Published: (2022)

Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review
by: Nikolaos Velidakis, et al.
Published: (2024)

Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate
by: Nashid Farhan, et al.
Published: (2021)

Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic
by: Donaldson M, et al.
Published: (2013)

The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis
by: S. P. Abdullaev, et al.
Published: (2020)

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER
by: I. S. Yavelov
Published: (2016)

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions
by: Xin Li, et al.
Published: (2020)

Development and Pharmacokinetics of a Novel Acetylsalicylic Acid Dry Powder for Pulmonary Administration
by: Adam Pacławski, et al.
Published: (2022)

Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults
by: Sandy Van Hemelryck, et al.
Published: (2024)

Ex-vivo Ex-Vivo Absorption Study of a Novel Dabigatran Etexilate Loaded Nanostructured Lipid Carrier Using Non-Everted Intestinal Sac Model
by: haithem N Abed, et al.
Published: (2019)

Comparative Serum and Brain Pharmacokinetics of Quercetin after Oral and Nasal Administration to Rats as Lyophilized Complexes with β-Cyclodextrin Derivatives and Their Blends with Mannitol/Lecithin Microparticles
by: Konstantina Manta, et al.
Published: (2023)

Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe-/- mice
by: Julia Leipner, et al.
Published: (2021)

Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model
by: Udomsak Udomnilobol, et al.
Published: (2024)

Editorial of the Special Issue Titled "Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases"
by: Nikolaos P. E. Kadoglou
Published: (2024)

Dabigatran in the Treatment of Warfarin-Induced Skin Necrosis: A New Hope
by: Christos Bakoyiannis, et al.
Published: (2016)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
by: Jong-Min Kim, et al.
Published: (2022)

Varenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression
by: Mitsuhisa Koga, et al.
Published: (2020)

Pharmacokinetics and Pharmacogenetics of Dabigatran
by: A. V. Savinova, et al.
Published: (2021)

Yellow Wine Polyphenolic Compounds Inhibit Matrix Metalloproteinase-2, -9 Expression and Improve Atherosclerotic Plaque in LDL-Receptor-Knockout Mice
by: Xiaoya Zhai, et al.
Published: (2014)

Caffeic acid protects against atherosclerotic lesions and cognitive decline in ApoE−/− mice
by: Rui Sun, et al.
Published: (2023)

Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice
by: Zuo Q, et al.
Published: (2022)

Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban
by: Qianxing Zhou, et al.
Published: (2011)

A2A adenosine receptor-mediated increase in coronary flow in hyperlipidemic APOE–knockout mice
by: Teng B, et al.
Published: (2011)

The new way of Dabigatran reversal - Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019)

DABIGATRAN AND DENTAL EXTRACTIONS - Case Report
by: Atanaska S. Dinkova, et al.
Published: (2017)

The new way of Dabigatran reversal - Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019)

Hesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages
by: Mitsuhisa Koga, et al.
Published: (2020)

GARP and GARP-Treated tDC Prevented the Formation of Atherosclerotic Plaques in ApoE−/- Mice
by: Cai Y, et al.
Published: (2021)

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
by: S. V. Moiseev
Published: (2015)

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
by: S. V. Moiseev
Published: (2015)

SAFETY ISSUES IN THE TREATMENT OF PATIENTS TAKING DABIGATRAN
by: E. S. Kropacheva
Published: (2016)